India Pharma Outlook Team | Friday, 05 December 2025
Astrazeneca's presence at the 2025 ASH Annual Meeting is the largest sharpe in the history of ASH and represents Astrazeneca's continuing efforts to lead the way in haematology.
The company's 65 abstracts represent an impressive milestone across eight of Astrazeneca's innovative medicines, showing the continued expansion of treatments already approved and in development for the future.
This year’s spotlight includes updated Phase I results for surovatamig, a CD19xCD3 T-cell engager, showing three-year follow-up data in relapsed or refractory follicular lymphoma. AstraZeneca is also unveiling the first look at its investigational BCMAxCD19 CAR T therapy, AZD0120, in multiple myeloma through the DURGA-1 study.
Also Read: Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections
Long-term findings from the ECHO Phase III trial will detail how Calquence combined with bendamustine and rituximab performs in first-line mantle cell lymphoma. For rare disease care, Alexion will share new Phase III results on Ultomiris in pediatric HSCT-TMA.
Anas Younes, senior vice president, haematology R&D and chief medical officer, AstraZeneca, said: “We are advancing a broad pipeline of investigational therapies with the potential to redefine patient care across multiple types of blood cancer. At ASH, we are sharing meaningful progress with early efficacy and safety data for AZD0120, our first cell therapy, in multiple myeloma, and for surovatamig, a novel T-cell engager, in B-cell malignancies.”
The update also includes further data regarding the safety and effectiveness of surovatamig in B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma. Further data from investigator-initiated study of AZD0120 in newly diagnosed, high-risk multiple myeloma.
Early clinical data on the use of Calquence in combination with venetoclax and rituximab for previously untreated mantle cell lymphoma. New subgroup findings from AMPLIFY, as well as detailed evaluations of Voydeya for PNH. Additionally, Astrazeneca has highlighted additional real-world evidence of Ultomiris’ benefit to key patient groups.
